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Abstract
Background: We have searched if plasma high density lipoprotein-cholesterol (HDL-C) concentration interferes
simultaneously with whole-body cholesterol metabolism and insulin sensitivity in normal weight healthy adult
subjects.
Methods: We have measured the activities of several plasma components that are critically influenced by insulin
and that control lipoprotein metabolism in subjects with low and high HDL-C concentrations. These parameters
included cholesteryl ester transfer protein (CETP), phospholipid transfer protein (PLTP), lecithin cholesterol acyl
transferase (LCAT), post-heparin lipoprotein lipase (LPL), hepatic lipase (HL), pre-beta-1HDL, and plasma sterol
markers of cholesterol synthesis and intestinal absorption.
Results: In the high-HDL-C group, we found lower plasma concentrations of triglycerides, alanine aminotransferase,
insulin, HOMA-IR index, activities of LCAT and HL compared with the low HDL-C group; additionally, we found
higher activity of LPL and pre-beta-1HDL concentration in the high-HDL-C group. There were no differences in the
plasma CETP and PLTP activities.
Conclusions: These findings indicate that in healthy hyperalphalipoproteinemia subjects, several parameters that
control the metabolism of plasma cholesterol and lipoproteins are related to a higher degree of insulin sensitivity.
Keywords: Insulin resistance, HDL-C concentration, Lipoprotein lipases, Lecithin cholesterol acyl transferase,
Pre-beta1 HDL, Plasma cholesterol metabolism markers, Cholesteryl ester transfer protein, Phospholipid transfer
protein
Background
The low plasma concentration of high density lipoprotein
cholesterol (HDL-C) is an independent risk factor for is-
chemic heart disease and has complex multifactorial
causes involving the actions of many genes. HDL particles
have several functions, including reverse cholesterol trans-
port and antioxidant, anti-inflammatory and antithrombo-
genic activities. The metabolic disturbances that cause
variations in the plasma HDL-C concentration have been
investigated in the genetic and secondary causes of dyslip-
idemia, such as obesity, insulin resistance, metabolic syn-
drome, ischemic heart disease and under the effect of
several pharmacological agents [1]. Nevertheless, the pre-
cise mechanisms by which HDL particles prevent athero-
sclerosis are unknown. There has been considerable effort
in utilizing genome-wide association to conclude that a
genetic variant near IRS1 is associated with type 2 dia-
betes, insulin resistance and hyperinsulinemia. However,
no clues have ever been provided with regard to the pri-
mary cause of the above mentioned associations with the
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regulation of the plasma HDL concentration or metabol-
ism rate, leaving aside rates of cholesterol metabolism [2].
The plasma HDL-C concentration may play a role as
an independent contributor to the pathogenesis of type
2 diabetes mellitus [3]. Premature atherosclerosis is re-
lated to several HDL-dependent activities that include a
diminished cell cholesterol efflux capacity by HDL [4].
Interestingly, the ABCA1 receptor is considered a major
factor in the maintenance of the plasma HDL-C concen-
tration and for cell cholesterol efflux essential to prevent
pancreatic islet lipid accumulation [5] and carriers of
loss-of-function mutations in ABCA1 show impaired in-
sulin secretion with [6] or without insulin resistance [7].
Also, certain ABCA1 genotypes have been related to in-
creased risk of diabetes mellitus in humans with [8,9] or
without [10] low HDL concentrations in plasma. Mice
lacking Abca1 have impaired glucose tolerance [11] al-
though in the LDLr knockout mouse model no associa-
tions were observed between the quantitative trait loci of
atherosclerosis and levels of total cholesterol, HDL-C, in-
sulin or body weight [12]. Also, in non-insulin dependent
diabetes mellitus pancreatic beta cells may fail to compen-
sate for insulin resistance and the ABCA1 receptor, a cel-
lular cholesterol transporter, plays a role as a regulator of
cholesterol homeostasis and insulin secretion in these cells
[13]. Furthermore, HDL exerts insulin-sensitizing effects
enhancing the glucose disposal in type 2 diabetes mellitus
patients [14].
Several investigations have dealt with the interactions
of dyslipidemia, insulin resistance and HDL lipidome.
However, these investigations have invariably been
biased by other factors that independently interfere with
the metabolism of HDL, such as variations in the body
mass index, waist circumference, plasma triglyceride
concentration, and age or gender differences between
the investigated groups [15-18]. These variables make it
impossible to ascertain a cause/effect relationship be-
tween the HDL concentration and insulin sensitivity.
High cholesterol synthesis and low cholesterol absorp-
tion have been associated with metabolic syndrome [19],
insulin resistance [20] and type 2 diabetes, independ-
ently of body weight [21]. We have previously shown
that healthy, non-obese adults with a high plasma
HDL-C concentration have greater plasma concentrations
of a cholesterol synthesis marker (lathosterol) and dimin-
ished concentrations of intestinal dietary cholesterol ab-
sorption markers (campesterol and β-sitosterol) compared
with low-HDL-C participants [22].
According to recent publications the relationship of
plasma HDL-C and insulin activity seems more complex
than previously reported. HDL-C plasma concentration
was related to angiopoietin-3 like (Angptl3), which is an
inhibitor of lipoprotein lipase activity, and to insulin sensi-
tivity [23]. Also, HDL-C concentration may be influenced
by insulin as suggested by a study in China relating lipo-
protein lipase, vitamin D and insulin resistance [24]. In
fact, insulin sensitivity likely explains the role of insulin on
plasma HDL-C concentration because patients with insu-
linoma without insulin resistance that had been matched
with controls for age and BMI do not increase the produc-
tion rate of high density lipoprotein apolipoprotein AI
which seems to be more dependent on the apoAI frac-
tional catabolic rate [25].
We have then hypothesized that plasma HDL-C con-
centrations independently of an increased body mass
index, age or gender might influence insulin sensitiv-
ity. Searching for possible causes we measured the
activities of cholesteryl ester transfer protein (CETP),
phospholipid transfer protein (PLTP), lecithin:cholesterol
acyltransferase (LCAT), post-heparin lipoprotein lip-
ase (LPL) and hepatic lipase (HL) in normal weight
healthy adult subjects with low and high plasma HDL-C
concentrations.
Methods
Subjects
Healthy volunteers (n = 73, 41 men and 32 women) with a
plasma HDL-C concentration < 40 mg/dL or > 60 mg/dL,
between the ages of 20 – 74 years, and with a BMI < 30
Kg/m2 were selected from the following institutions: the
Lipid Clinic Disorders Service of the Endocrinology and
Metabolism Unit of the Clinical Hospital of the Faculty
of Medicine, University of São Paulo (HCFMUSP);
the Clinical Hospital at the University of Campinas
(UNICAMP); health centers of the city of Campinas; and
the Laboratory of Ouro Verde Hospital, Campinas, São
Paulo State, Brazil. All participants were informed of
the objectives of the study and signed an informed
written consent in accordance with the research protocols
approved by the Ethics Committee of HCFMUSP and
UNICAMP. The cases included in this study had previ-
ously been reported [22]. The exclusion criteria were obes-
ity, metabolic syndrome, diabetes mellitus, uncontrolled
thyroid function disorder, liver and kidney failure, smoking,
alcohol abuse and the use of medications that may inter-
fere with cholesterol metabolism, such as hormonal re-
placement therapy and blood lipid-lowering drugs.
Measurements
Blood was drawn after a 12 h-fasting period. The blood
samples were treated with 10% EDTA, and the plasma
was immediately separated for further analysis. Plasma
glucose, cholesterol and triglyceride concentrations
were measured using commercially available enzymatic-
colorimetric methods (Labtest Diagnostica, Brazil and
Roche Diagnostics Corp, Indianapolis, IN, respectively).
The plasma LDL-C concentration was calculated using
the Friedewald formula [26].
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The plasma insulin concentration was measured by an
immunofluorometric assay using AutoDELFIA (Perkin
Elmer Inc., Waltham, Mass.,USA), and the homeostasis
model assessment insulin resistance (HOMA-IR) was
calculated according to the following formula: Glucose
(mmol/L) × Insulin (mU/L)/22.5. The alanine amino-
transferase (ALT) and aspartate aminotransferase (AST)
activities were measured by the kinetic method, and the
high sensible plasma C-reactive protein (hsCPR) concen-
tration was measured by immunoturbidimetric assay.
The serum amyloid A (SAA) concentration was mea-
sured by nephelometry (Siemens Healthcare Diagnostics,
Deerfield, IL, USA), and the levels of apolipoproteins
were measured by immunoturbidimetric assays (Randox,
Crumlin Co., Antrin, Ireland). The plasma concentra-
tions of markers of intestinal cholesterol absorption
(campesterol and β-sitosterol) and of cholesterol synthe-
sis (desmosterol and lathosterol) that had been pre-
sented in our previous publication [22] were measured
by gas chromatography (GC) coupled to a mass spectro-
photometer (MS) (Shimadzu GCMS-QP2010 Plus, Kyoto,
Japan), with the software GCMS solution ver. 2.5 [27] and
are included in the present report. The LCAT-mediated
cholesterol esterification rate was measured using en-
dogenous substrates labeled with 14C-cholesterol, accord-
ing to Dobiasova et al. [28], and the CETP activity which
indirectly indicates CETP mass was measured by a radio-
isotopic assay using an exogenous substrate, as previously
described [22]. The PLTP activity was measured using an
exogenous radiometric assay, as described by Jauhiainen
and Ehnholm [29]. HL and LPL activities were measured
using a method adapted from Ehnholm [30]. Briefly, the
plasma samples were drawn 15 minutes after intravenous
heparin administration (100 U/Kg of body weight), and
the lipase activities were measured via liberated free fatty
acids using radiolabeled triolein emulsion as the substrate
and 1 M NaCl as the LPL inhibitor. The pre-beta1-HDL
concentration was measured using an enzyme-linked im-
munosorbent assay (ELISA) from Daiichi Pure Chemicals
Co. (Tokyo, Japan).
Statistical analysis
The statistical analyses were performed using GraphPad
Prism version 4.0 (GraphPad Softwares, USA). Compari-
sons between groups were performed using Student
t test. The significance level chosen was p < 0.05, and the
results are presented as mean ± SD. A correlation matrix
study was performed with GraphPad Instat version 3.05
(GraphPad Softwares, USA).
Results
Anthropometric and laboratorial data are presented in
Table 1. The plasma concentration of triglycerides (TG),
insulin, HOMA-IR index and ALT were lower in the
high-HDL group compared with the low-HDL-C group.
As expected, the apolipoprotein (apo) AI and apo E con-
centrations were higher in the high-HDL-C group. For
being slightly older than the hypoalphalipoproteinaemics
a diminished degree of insulin sensitivity should have
been expected in our hyperalphalipoproteinaemics and
yet the opposite was found which reinforces the conclu-
sion that our results were not biased by age differences
between the groups.
The high-HDL-C group presented lower LCAT and
post-heparin hepatic lipase activities and higher post-
heparin lipoprotein lipase activity and pre-beta-1-HDL
concentration than did the low-HDL-C group. Plasma
LCAT activity significantly reduced in the hyperalphali-
poproteinaemic cases compared with the hypoalphalipo-
proteinaemic cases is congruent with the elevated plasma
LCAT activity found in metabolic syndrome attributed to
insulin resistance [31]. These results are supported by a
report of LCAT-null mice being protected from both diet-
induced obesity and insulin resistance and from simultan-
eously developing increased hepatic insulin sensitivity
[32]. The plasma exogenous CETP and PLTP activities did
not vary between our two HDL-C groups and therefore
did not explain their different HDL-C concentrations. The
latter is likely due to the combination of the remarkable
differences in the post-heparin lipoprotein and hepatic lip-
ase activities in addition to a modest, although significant,
LCAT variation.
In an attempt to elucidate the origin of the metabolic
processes involved, a univariate correlations of all the
parameters measured was performed. Table 2 presents
only the results that were highly significant (greater
than ± 0.5, p < 0.05), and therefore capable of indicat-
ing meaningful dependent relationships. Certain signifi-
cant relationships were predictable according to the
literature, such as the waist circumference and body mass
index (BMI) (a), the effect of age raising the plasma LDL-
C concentration (b), lowering the post-heparin lipoprotein
lipase (c) [33], an inverse association of plasma TG and
HDL-C concentrations (d) as well as a marker of insulin
resistance (HOMA-IR) varying directly with the waist
circumference (e) [34] and inversely with post-heparin
LPL activity (f) [35]. LPL varied inversely with the
average arterial blood pressure (g), reinforcing the
state of insulin resistance typical of the metabolic
syndrome that characterized the low-HDL-C cases;
however, potential genetic reasons for this association
cannot be ignored [36]. ALT activity associated with
the marker of cholesterol body synthesis (desmos-
terol) (h) likely reinforces the enhanced insulin sensi-
tivity [37] in the high-HDL-C cases. However, as a
marker of cholesterol synthesis, desmosterol alone did
not differ between the HDL-C concentration groups in
our previous investigation, which served as a database for
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the present report [22]. In the latter study, plasma
campesterol (i) was shown to be one of the two
markers of cholesterol absorption. Its concentration
was greater in the high-HDL-C group than in the
low-HDL-C group. The plasma campesterol concen-
tration is shown here to correlate with the partici-
pants’ age, characterizing a new, interesting finding
because the absorption data had been properly cor-
rected for the plasma cholesterol concentration and
body mass index. In contrast, lathosterol, which is a
significant marker of whole-body cholesterol synthe-
sis, was not only elevated in the low-HDL-C cases
but also correlated with the plasma LDL-C concen-
tration (j).
Discussion
As recently reviewed, HDL-C is controlled simultaneously
by several factors, such as LCAT, PLTP, CETP, and periph-
eral and hepatic post-heparin lipoprotein lipases, which by
themselves are regulated by insulin [38], as shown in the
present study, in addition to the angiopoietin-3-like gene
as indicated in a recent study [23].
Challenging the notion that LCAT is needed for an
efficient atheroprotection, no association between ca-
rotid intima/media thickness (IMT) and LCAT was ob-
served in men, and carotid IMT increased with LCAT
quartiles in women [39]. However, in a Danish population,
ischemic heart disease was associated with low LCAT and
high pre-beta1-HDL concentrations [40]. In contrast, our
Table 1 Anthropometric data, blood chemistry and lipoprotein metabolism data in healthy participants with low
plasma HDL-C vs. high plasma HDL-C concentration
Low HDL High HDL P
Gender 21 men/16 women 20 men/16 women
Age (year) 37 ± 11 45 ± 14 0.022
BMI (Kg/m2) 24.0 ± 2.4 23.5 ± 3.3
Waist (cm) 80 ± 9 80 ± 9
Glucose (mg/dL) 83 ± 8 84 ± 8
Insulin (μU/mL) 6.5 ± 3.1 4.4 ± 1.8 <0.001
HOMA index 1.35 ± 0.67 0.91 ± 0.39 0.001
Triglycerides (mg/dL) 97 ± 33 71 ± 34 0.002
Cholesterol (mg/dL) 159 ± 25 186 ± 30 <0.001
HDL-C (mg/dL) 34 ± 4 79 ± 13 <0.001
LDL-C (mg/dL) 106 ± 22 93 ± 22 0.018
VLDL (mg/dL) 19 ± 7 14 ± 7 0.001
TG/HDL ratio 3.00 ± 1.32 0.91 ± 0.42 <0.001
Apo AI (mg/dL) 84.8 ± 15.5 124.9 ± 19.4 <0.001
Apo B (mg/dL) 75.4 ± 21.7 71.8 ± 17.1
Apo CII (mg/dL) 3.1 ± 1.9 3.1 ± 1.5
Apo CIII (mg/dL) 7.3 ± 3.1 6.7 ± 4.4
Apo E (mg/dL) 2.1 ± 0.8 3.2 ± 1.2 <0.001
ALT (U/L) 24 ± 16 16 ± 5 0.005
AST (U/L) 20 ± 6 19 ± 3
hsCRP (mg/L) 1.7 ± 2.0 2.1 ± 4.6
SAA (mg/L) 3.2 ± 2.8 6.4 ± 10.5
CETP (%CE) 13.6 ± 5.3 13.5 ± 4.5
PLTP (nmolPC/mL/h) 6,247 ± 1,851 6,439 ± 1,617
LCAT (%CE) 3.71 (2.48-5.02) 2.68 (1.63-3.61) 0.011
LPL (nmFFA/mL/h) 2,403 ± 1,304 4,597 ± 2,616 <0.001
HL (nmFFA/mL/h) 4,517 ± 1,622 3,159 ± 1,424 <0.001
Pre-beta1-HDL (ng/mL) 11.8 ± 5.7 (n = 33) 22.4 ± 22.5 (n = 34) 0.008
ALT, Alanine aminotransferase. Apo, Apolipoprotein. AST, Aspartate aminotransferase. BMI, Body mass index. CETP, Cholesteryl ester transfer protein. HL. Hepatic
lipase. HOMA, Homeostasis model assessment. LCAT, Lecithin: cholesterol acyltransferase. LPL, Lipoprotein lipase. hsCPR, C- reactive protein. SAA, Serum amyloid A.
PLTP, Phospholipid transfer protein. Student t test, low HDL-C vs. high HDL-C. Data are presented as mean ± SD. P < 0.05. Pre-beta1-HDL (n = 33 low HDL-C; n = 34
high HDL-C). PLTP, HL and LPL (n = 34 low HDL-C; n = 66 high HDL-C).
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hyperalphalipoproteinaemia cases showed low LCAT
activity and high pre-beta1-HDL. This result was ex-
pected given the diminished LCAT conversion of the
precursor pre-beta1-HDL into the larger HDL likely being
overcome by a fast generation of pre-beta1-HDL and HDL
secondarily to an increased post-heparin lipoprotein lipase
activity. Our observation that the hyperalphalipoprotei-
naemic participants have increased post-heparin lipo-
protein lipase activity and diminished hepatic lipase
activity compared with the hypoalphalipoproteinaemic
participants is in agreement with a previous report
[41]. Due to the high-HDL insulin-sensitive state in
hyperalphalipoproteinaemia binding and internalization
rates of triglyceride-enriched HDL may slow down [42].
Thus, our results conform to the following chain of events
described in a previous review [43]. In insulin-sensitive
cases - as our high-HDL-C participants - the conse-
quent enhanced post-heparin lipoprotein lipase activ-
ity induces HDL production that, combined with the
diminished hepatic lipoprotein lipase, further in-
creases the HDL particle size and quantity. In hyper-
alphalipoproteinemia cases, we found a diminished
TG/HDL-C plasma ratio that has been deemed as
critically dependent on insulin activity [44]. Although
the plasma CETP activity measured by the exogenous
method that reflects the plasma CETP concentration
[22] did not differ between the two groups the low
TG/HDL-C likely is consequent to decreased endogen-
ous CETP activity due to a diminished triglyceride
availability from apoB-containing LP for exchange
with HDL cholesteryl ester in hyperalphalipoprotaei-
nemia cases.
In agreement with a primary role for insulin sensitivity
in cholesterol metabolism and, to a considerable extent, in
plasma HDL-C concentration variation, we found a
diminished ALT level within the “reference” range in
hyperalphalipoprotaeinemia cases, a result compatible
with other reports relating ALT to insulin sensitivity [37].
Even in the absence of diabetes mellitus, changes in
cholesterol metabolism are important predictors of
cardiovascular disease, as has been recently shown
Weingärtner et al. [45], however, that work did not
investigate the relationship with insulin resistance or with
plasma HDL-C concentrations. Furthermore, there has
been clinical evidence in healthy, lean adult humans sup-
porting insulin sensitivity-dependency on the abdominal
fat quantity simultaneously with plasma HDL-C concen-
tration variations [46]. Our present and previous findings
[22] indicate that, in hyperalphalipoproteinemia, variations
in several parameters that control the plasma lipoprotein
metabolism are related to an increased degree of insulin
sensitivity. In support of this conclusion, a study in India
on normal-weight offspring with type 2 diabetes mellitus
that were matched with controls of comparable age
showed that the former had lower plasma HDL-C concen-
trations and higher values of plasma insulin [47]. The
latter finding suggests that the development of dia-
betes mellitus is preceded by such changes, although
not linked to any specific genetic cause.
Further investigation is required utilizing more reliable
methods to measure insulin sensitivity in these case,
such as the clamp technique.
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